Relapsed and refractory pediatric acute myeloid leukemia: Current and emerging treatments

Pediatric Drugs

Volumn 16, Issue 2, 2014, Pages 151-168

  Davila, Jennifer ^a   Slotkin, Emily ^a   Renaud, Thomas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMALGAM; AMPHOTERICIN; ANTHRACYCLINE; BORTEZOMIB; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; LESTAURTINIB; LINTUZUMAB; MIDOSTAURIN; MITOXANTRONE; NAVELBINE; QUIZARTINIB; SEMAXANIB; SORAFENIB; SU 1 1428; SUNITINIB; THIOTEPA; TIOGUANINE; TOPOTECAN; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILDHOOD LEUKEMIA; DISEASE COURSE; DNA METHYLATION; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LONG TERM SURVIVAL; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY LEUKEMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; RECURRENCE; SURVIVAL RATE; TREATMENT FAILURE;

EID: 84898413310     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0048-y     Document Type: Article

References (216)

1. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer. 2008;112(2):416-32.
2. Puumala SE, Ross JA, Aplenc R, et al. Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer 2013;60(5):728-33
3. Kaspers GJ. Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2012;12(3):405-13.
4. Masaoka T, et al. A phase II study of mitoxantrone in acute leukemia. Invest New Drugs. 1985;3(2):197-201.
5. Rubnitz JE, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543-52.
6. Rizzari C, et al. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease. Expert Rev Anticancer Ther. 2011;11(9):1391-401.
7. Gorman MF, et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer. 2010;55(3):421-9.
8. Lie SO, et al. Long-term results in children with AML: NOPHO-AML Study Group - report of three consecutive trials. Leukemia. 2005;19(12):2090-100.
9. Gibson BE, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130-8.
10. Dluzniewska A, et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia. 2005;19(12):2117-24.
11. Lange BJ, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008;111(3):1044-53.
12. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005;19(12):2025-9.
13. Jastaniah W, Abrar MB, Khattab TM. Improved outcome in pediatric AML due to augmented supportive care. Pediatr Blood Cancer. 2012;59(5):919-21.
14. Riley LC, et al. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol. 1999;106(2):436-44.
15. Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012;119(25):5980-8.
16. Hann IM, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997;89(7):2311-8.
17. Gibson BE, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155(3):366-76.
18. Buckley JD, et al. Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group. Cancer. 1989;63(8):1457-65.
19. Smith FO, et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005;19(12):2054-62.
20. Creutzig U, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21):4384-93.
21. Lehrnbecher T, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004;18(1):72-7.
22. Castagnola E, et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study. Pediatr Blood Cancer. 2010;55(6):1103-7.
23. Rubnitz JE, et al. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer. 2007;109(1):157-63.
24. Sander A, et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia. 2010;24(8):1422-8.
25. Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist. 2007;12(3):341-55.
26. Abrahamsson J, et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol. 2007;136(2):229-36.
27. Kaspers GJ, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599-607.
28. Webb DK, et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia. 1999;13(1):25-31.
29. Bunin NJ, et al. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol. 2008;26(26):4326-32.
30. Leung W, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120(2):468-72.
31. Alberts DS, et al. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs. 1985;3(2):101-7.
32. Sparano BM, et al. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. 2. Histologic and ultrastructural pathology. Cancer Treat Rep. 1982;66(5):1145-58.
33. Zbinden G, Beilstein AK. Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats. Toxicol Lett. 1982;11(3-4):289-97.
34. van Dalen EC, et al. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer. 2004;40(5):643-52.
35. Estey EH, et al. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep. 1983;67(4):389-90.
36. Meyer P, et al. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Invest New Drugs. 1985;3(2):203-6.
37. Arlin ZA, et al. Phase I-II trial of mitoxantrone in acute leukemia. Cancer Treat Rep. 1985;69(1):61-4.
38. Larson RA, et al. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol. 1987;5(3):391-7.
39. Vredenburgh JJ, et al. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. Med Pediatr Oncol. 1988;16(3):187-9.
40. Kaminer LS, et al. Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. Cancer. 1990;65(12):2619-23.
41. Saiki JH, et al. Mitoxantrone (dihydroxyanthracenedione) in acute leukemia: an evaluation of two treatment schedules by the Southwest Oncology Group. Invest New Drugs. 1993;11(2-3):197-200.
42. Bezwoda WR, et al. Mitoxantrone for refractory and relapsed acute leukemia. Cancer. 1990;66(3):418-22.
43. Ungerleider RS, et al. Phase I trial of mitoxantrone in children. Cancer Treat Rep. 1985;69(4):403-7.
44. Ho AD, et al. Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia. Cancer Treat Rep. 1986;70(8):1025-7.
45. Ho AD, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia - an active and well-tolerated regimen. J Clin Oncol. 1988;6(2):213-7.
46. Lazzarino M, et al. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia. Eur J Haematol. 1989;43(5):411-6.
47. Paciucci PA, et al. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Am J Clin Oncol. 1990;13(6):516-9.
48. McHayleh W, et al. Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin. Leuk Lymphoma. 2009;50(11):1848-53.
49. Paciucci PA, et al. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. Leukemia. 1987;1(7):565-7.
50. Paciucci PA, Cuttner J, Holland JF. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia. Am J Hematol. 1990;35(1):22-5.
51. Harousseau JL, et al. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia. Nouv Rev Fr Hematol. 1990;32(4):227-30.
52. Hiddemann W, et al. High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison. Semin Hematol. 1991;28(3 Suppl. 4):35-8.
53. Keskin A, et al. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. Acta Haematol. 1994;92(1):14-7.
54. Wells RJ, et al. Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. Med Pediatr Oncol. 1994;22(4):244-9.
55. MacCallum PK, et al. Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients. Ann Hematol. 1995;71(1):35-9.
56. Link H, et al. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia. Haematol Blood Transfus. 1990;33:322-5.
57. Amadori S, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol. 1991;9(7):1210-4.
58. Spadea A, et al. Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. Leukemia. 1993;7(4):549-52.
59. Archimbaud E, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol. 1995;13(1):11-8.
60. Lee SS, et al. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. Leuk Res. 2009;33(4):511-7.
61. Kohrt HE, et al. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Am J Hematol. 2010;85(11):877-81.
62. Trifilio SM, et al. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leuk Res. 2012;36(4):394-6.
63. Chevallier P, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol. 2008;26(32):5192-7.
64. Wierzbowska A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80(2):115-26.
65. Luo S, et al. Clinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemia. Exp Ther Med. 2013;5(3):982-6.
66. Hanel M, et al. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie. 2001;24(4):356-60.
67. Eom KS, et al. FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. Med Oncol. 2011;28(Suppl. 1):S462-70.
68. Advani AS, et al. A phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse. Clin Lymphoma Myeloma Leuk. 2010;10(6):473-6.
69. Wells RJ, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol. 2003;21(15):2940-7.
70. Creutzig U, et al. Improved treatment results in children with AML: results of study AML-BFM 93. Klin Padiatr. 2001;213(4):175-85.
71. Creutzig U, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12):2030-42.
72. Bonate PL, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov. 2006;5(10):855-63.
73. Jeha S, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004;103(3):784-9.
74. Jeha S, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009;27(26):4392-7.
75. Abd Elmoneim A, et al. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Pediatr Blood Cancer. 2012;59(7):1252-8.
76. Locatelli F, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol. 2009;147(3):371-8.
77. Hijiya N, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009;23(12):2259-64.
78. Hijiya N, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118(23):6043-9.
79. Inaba H, et al. Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. Br J Haematol. 2012;156(2):275-9.
80. Miano M, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma. 2012;53(9):1693-8.
81. O'Connor D, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br J Haematol. 2011;154(4):482-5.
82. Faderl S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105(3):940-7.
83. Faderl S, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006;108(1):45-51.
84. Becker PS, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011;155(2):182-9.
85. Agura E, et al. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist. 2011;16(2):197-206.
86. Scappini B, et al. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Am J Hematol. 2012;87(12):1047-51.
87. Kolb EA, Steinherz PG. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia. 2003;17(10):1967-72.
88. Steinherz PG, et al. Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group. Leuk Lymphoma. 2002;43(10):1945-50.
89. Steinherz PG, et al. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer. 2010;54(5):687-93.
90. Shukla N, Kobos R, Renaud TM, Steinherz L, Steinherz PG. Phase II trial of clofarabine in combination with topotecan, vinorelbine, and thiotepa (TVTC) in pediatric patients with refractory or relapsed acute leukemia. Blood. ASH Annual Meeting Abstracts. 2012;120:1514.
91. Carrera CJ, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest. 1990;86(5):1480-8.
92. Santana VM, et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992;10(3):364-70.
93. Gandhi V, et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996;87(1):256-64.
94. Robak T, et al. Combination regimen of cladribine (2- chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2000;39(1-2):121-9.
95. Van Den Neste E, et al. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. Ann Hematol. 1998;76(1):19-23.
96. Kornblau SM, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996;10(10):1563-9.
97. Santana VM, et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood. 1994;84(4):1237-42.
98. Krance RA, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol. 2001;19(11):2804-11.
99. Crews KR, et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002;20(20):4217-24.
100. Rubnitz JE, et al. Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. Leuk Res. 2004;28(4):349-52.
101. Inaba H, et al. Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer. 2010;116(1):98-105.
102. Warrell RP Jr, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4(1):74-9.
103. Vahdat L, et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood. 1994;84(10):3429-34.
104. Cheson BD, et al. Neurotoxicity of purine analogs: a review. J Clin Oncol. 1994;12(10):2216-28.
105. Lowenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013;121(1):26-8.
106. Lowenberg B, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027-36.
107. Yamauchi T, et al. Close correlation of 1-beta-D-arabinofuranosylcytosine 5-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-d-arabinofuranosylcytosine therapy for acute myelogenous leukemia. Jpn J Cancer Res. 2001;92(9):975-82.
108. Gandhi V, et al. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993;10(Suppl.):109-14.
109. Gandhi V, et al. Minimum dose of fludarabine for the maximal modulation of 1-beta-d-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997;3(9):1539-45.
110. Gandhi V, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11(1):116-24.
111. Rayappa C, McCulloch EA. A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside. Leukemia. 1993;7(7):992-9.
112. Tosi P, et al. Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia. 1994;8(12):2076-82.
113. Clavio M, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica. 1996;81(6):513-20.
114. Plunkett W, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 1993;20(5 Suppl. 7):2-12.
115. Huhmann IM, et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol. 1996;73(6):265-71.
116. Visani G, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia. 1994;8(11):1842-6.
117. Avramis VI, et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res. 1998;4(1):45-52.
118. Leahey A, et al. A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML). J Pediatr Hematol Oncol. 1997;19(4):304-8.
119. Fleischhack G, et al. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol. 1998;102(3):647-55.
120. Fleischhack G, et al. IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF) - an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents: initial results of a pilot study. Klin Padiatr. 1996;208(4):229-35.
121. Tavil B, et al. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience. Pediatr Hematol Oncol. 2010;27(7):517-28.
122. Dinndorf PA, et al. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J Clin Oncol. 1997;15(8):2780-5.
123. Yalman N, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr. 2000;42(3):198-204.
124. Tardi P, et al. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129-39.
125. Bellott R, Pouna P, Robert J. Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome. J Chromatogr B Biomed Sci Appl. 2001;757(2):257-67.
126. Bellott R, et al. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 2001;47(1):15-21.
127. Camera A, et al. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Ann Hematol. 2009;88(2):151-8.
128. Clavio M, et al. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol. 2004;83(11):696-703.
129. Cortes J, et al. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs. 1999;17(1):81-7.
130. Russo D, et al. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Ann Hematol. 2002;81(8):462-6.
131. Meshinchi S, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654-61.
132. Abu-Duhier FM, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000;111(1):190-5.
133. Gale RE, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-84.
134. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532-42.
135. Frohling S, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372-80.
136. Smith CC, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260-3.
137. Pratz KW, et al. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010;115(7):1425-32.
138. Levis M. FLT3/ITD AML and the law of unintended consequences. Blood. 2011;117(26):6987-90.
139. Fathi A, Levis M. FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol. 2011;18(2):71-6.
140. Fabian MA, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23(3):329-36.
141. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116(24):5089-102.
142. Inaba H, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol. 2011;29(24):3293-300.
143. Widemann BC, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012;18(21):6011-22.
144. Zarrinkar PP, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984-92.
145. Cooper T, Sposto R, Cassar J, et al. A phase I study of AC220 in combination with cytarabine and etoposide in relapsed/refractory childhood ALL and AML: a Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study. ASH Annual Meeting Abstracts. 2012;120:3605
146. Arrigo AP, et al. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature. 1988;331(6152):192-4.
147. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol. 2002;14(6):628-34.
148. Orlowski RZ. Proteasome inhibitors in cancer therapy. Methods Mol Biol. 2005;301:339-50.
149. Vink J, Cloos J, Kaspers GJ. Proteasome inhibition as novel treatment strategy in leukaemia. Br J Haematol. 2006;134(3):253-62.
150. Teicher BA, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5(9):2638-45.
151. Riccioni R, et al. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Br J Haematol. 2007;139(2):194-205.
152. Orlowski RZ, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20(22):4420-7.
153. Cortes J, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004;10(10):3371-6.
154. Horton TM, et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58(1):13-23.
155. Soligo D, et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol. 2001;113(1):126-35.
156. Pigneux A, et al. Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins. Cancer Biol Ther. 2007;6(4):603-11.
157. Orlowski RZ, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105(8):3058-65.
158. Attar EC, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008;14(5):1446-54.
159. Walker AR, et al. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2013;54(9):1996-2002
160. Horton TM, Perentesis J, Gamis AS, et al. A phase 2 study of bortezomib combined with reinduction chemotherapy in children and young adults with recurrent, refractory or secondary acute myeloid leukemia: a Children's Oncology Group (COG) study [Abstract 3580]. ASH Annual Meeting Abstracts, 2012. 120.
161. Schoofs T, Berdel WE, Muller-Tidow C. Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia. Epub 2013 Aug 20.
162. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16(4):168-74.
163. Oki Y, Aoki E, Issa JP. Decitabine - bedside to bench. Crit Rev Oncol Hematol. 2007;61(2):140-52.
164. Pinto A, et al. 5-Aza-2-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood. 1984;64(4):922-9.
165. Cashen AF, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556-61.
166. Blum KA, et al. Phase I trial of low dose decitabine targeting DNA
167. Thomas XG, Dmoszynska A, Wierzbowska A, et al. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. J Clin Oncol. 2011;29(15 Suppl.):6504.
168. Ganetsky A, Adel NG, Frattini MG, Maslak PG, Heaney ML, Jurcic JG, Tallman MS. Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience. J Clin Oncol. 2011;29(15 Suppl.):6593.
169. George TJ, Woolery JE, Wetzstein GA, et al. A retrospective study of decitabine for the treatment of relapsed or refractory acute myeloid leukemia: lack of response observed in a heavily pretreated population. ASH Annual Meeting Abstracts. 2010;116:2186.
170. Ritchie EK, Arnason J, Feldman EJ, et al. Decitabine-based salvage therapy in adults with acute myeloid leukemia. ASH Annual Meeting Abstracts. 2009;114:2063.
171. Ritchie EK, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54(9):2003-7.
172. Phillips CL, et al. Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. Br J Haematol. 2013;161(3):406-10.
173. Marks P, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1(3):194-202.
174. Silva G, et al. Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. PLoS One. 2013;8(1):e53766.
175. Garcia-Manero G, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111(3):1060-6.
176. Garcia-Manero G, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012;30(18):2204-10.
177. Gojo I, et al. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res. 2013;19(7):1838-51.
178. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495-7.
179. Creutzig U, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood. 1995;86(8):3097-108.
180. Dinndorf PA, et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986;67(4):1048-53.
181. Andrews RG, et al. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood. 1986;68(5):1030-5.
182. Scheinberg DA, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9(3):478-90.
183. Caron PC, et al. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 1992;52(24):6761-7.
184. Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res. 1998;4(6):1421-8.
185. Feldman E, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 2003;17(2):314-8.
186. Feldman EJ, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110-6.
187. Lancet JE, Sekeres MA, Wood BL, et al. Lintuzumab and low-dose cytarabine compared to placebo and low-dose cytarabine in patients with untreated acute myeloid leukemia (AML) 60 years and older: results of a randomized, double-blinded phase 2b study [Abstract no. 3613]. Blood 2011: ASH Annual Meeting Abstracts: 118
188. Hamann PR, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47-58.
189. Hamann PR, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia: choice of linker. Bioconjug Chem. 2002;13(1):40-6.
190. van Der Velden VH, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97(10):3197-204.
191. Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther. 2001;1(5):893-901.
192. Zwaan CM, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003;101(10):3868-71.
193. Reinhardt D, et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie. 2004;27(3):269-72.
194. Zwaan CM, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148(5):768-76.
195. Kaspers GJ, Zimmermann M, Fleischhack G, et al. Relapsed acute myeloid leukemia in children and adolescents: interim report of the international randomised phase III study relapsed AML 2001/01. ASH Annual Meeting Abstracts. 2006;108:2013
196. Arceci RJ, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 2005;106(4):1183-8.
197. Aplenc R, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2008;26(14):2390-3295.
198. Brethon B, et al. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol. 2008;143(4):541-7.
199. Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of southwest oncology group study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. ASH Annual Meeting Abstracts. 2009;114:790
200. Bross PF, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490-6.
201. Burnett AK, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-77.
202. Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-16.
203. Farhat H, et al. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association. Am J Hematol. 2012;87(1):62-5.
204. Vivier E, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44-9.
205. Leung W, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172(1):644-50.
206. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol. 2011;155(1):14-29.
207. Ruggeri L, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-100.
208. Giebel S, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814-9.
209. Miller JS, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-7.
210. Rubnitz JE, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955-9.
211. Iyengar R, et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy. 2003;5(6):479-84.
212. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376-83.
213. Berg M, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11(3):341-55.
214. Fujisaki H, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010-7.
215. Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
216. Ritchie DS, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. Epub 2013 Jul 8